Humacyte, Inc. (HUMAW)Durham, United States | NasdaqGS
0.00 USD
0.00
(-78.049%) ⇩
(Aug. 25, 2026, 3:59 p.m.
EDT)
|
Hot Take ↕ | Aug. 22, 2026, 4:02 a.m. EDT
The immediate outlook is severely bearish due to a catastrophic collapse in price momentum. Despite a recent headline suggesting a surge, the actual data reveals a freefall from 11 cents to 1 cent within a fortnight, indicating a violent capitulation event rather than a healthy breakout. This 90%+ drop in such a short window suggests a liquidity crisis or a fundamental re-rating that has crushed the chart structure, leaving no room for a short-term bounce. Looking further ahead, the business fundamentals are in freefall with negative returns on equity and assets, massive cash burn, and no revenue growth history to speak of. The lack of any price history beyond the recent crash makes a long-term assessment impossible, as there is no track record of survival or growth to evaluate. Finally, the company offers zero dividend income, providing no cushion for investors holding through this volatility. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 213.941 |
| Revenue per Share | 0.011 |
| Beta | 2.47 |
| Website | https://www.humacyte.com |
| Attribute | Value |
|---|---|
| Address1 | 2,525 East North Carolina Highway 54 |
| Ask | 0.1993 |
| Ask Size | 3 |
| Beta | 2.47 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 0.113 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0009 |
| Current Ratio | 6.207 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0039 |
| Day Low | 0.0009 |
| Debt To Equity | 213.941 |
| Display Name | Humacyte |
| Ebitda | -103,228,000 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -3.158 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0039 |
| Fifty Two Week High Change | -0.003 |
| Fifty Two Week High Change Percent | -0.7692308 |
| Fifty Two Week Low | 0.0009 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 9.0E-4 - 0.0039 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 251,023,924 |
| Free Cashflow | -58,393,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 184 |
| Fullday Change | -0.0032000002 |
| Fullday Change Percent | -78.04878 |
| Fullday Price | 0.0009 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -79,374,000 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Language | en-US |
| Long Business Summary | Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina. |
| Long Name | Humacyte, Inc. |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_107706507 |
| Net Income To Common | -96,668,000 |
| Open | 0.23 |
| Operating Cashflow | -97,193,000 |
| Operating Margins | -66.492615 |
| Phone | 919 313 9633 |
| Previous Close | 0.0041 |
| Price Hint | 4 |
| Price To Book | 0.007964602 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.367 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0032000002 |
| Regular Market Change Percent | -78.04878 |
| Regular Market Day High | 0.0039 |
| Regular Market Day Low | 0.0009 |
| Regular Market Day Range | 9.0E-4 - 0.0039 |
| Regular Market Open | 0.23 |
| Regular Market Previous Close | 0.0041 |
| Regular Market Price | 0.0009 |
| Regular Market Time | 1,787,687,990 |
| Regular Market Volume | 258,659 |
| Return On Assets | -0.49866 |
| Return On Equity | -5.47872 |
| Revenue Growth | 0.349 |
| Revenue Per Share | 0.011 |
| Sand P52 Week Change | 0.20204377 |
| Sector | |
| Sector Key | |
| Source Interval | 15 |
| State | NC |
| Symbol | HUMAW |
| Total Cash | 79,903,000 |
| Total Cash Per Share | 0.288 |
| Total Debt | 66,880,000 |
| Total Revenue | 2,121,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.158 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 258,659 |
| Website | https://www.humacyte.com |
| Zip | 27,713 |